Loading
MEF2D (Myocyte-specific enhancer factor 2D) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific, growth factor- and stress-induced genes. Mediates cellular functions not only in skeletal and cardiac muscle development, but also in neuronal differentiation and survival. Plays diverse roles in the control of cell growth, survival and apoptosis via p38 MAPK signalling in muscle-specific and/or growth factor-related transcription.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · MEF2D (Myocyte-specific enhancer factor 2D) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
MEF2D (Myocyte-specific enhancer factor 2D) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific, growth factor- and stress-induced genes.
No product in this corpus aims at MEF2D yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA MEF2D: RNA tissue enhanced (skeletal muscle 158 nTPM); high antibody staining in 34 normal tissues; highest cancer staining breast cancer (11 of 11 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas MEF2D tissue; Open Targets ENSG00000116604 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Breitbart R.E. et al, Development, 1993, "A fourth human MEF2 transcription factor, hMEF2D, is an early marker of the myogenic lineage". Source.
Sources: HGNC HGNC:6997 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14814 (protein name, function text, keywords and locations (REST API)); CIViC gene MEF2D (1 evidence items, 0 assertions, 1 variants; diseases: B-cell Acute Lymphoblastic Leukaemia (GraphQL API, CC0))
Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific, growth factor- and stress-induced genes. Mediates cellular functions not only in skeletal and cardiac muscle development, but also in neuronal differentiation and survival. Plays diverse roles in the control of cell growth, survival and apoptosis via p38 MAPK signalling in muscle-specific and/or growth factor-related transcription. Plays a critical role in the regulation of neuronal apoptosis. Location: Nucleus (UniProt). Locus 1q22 (HGNC).
RNA: tissue enhanced (skeletal muscle 158 nTPM), detected in all normal tissues.
Medium: Adipose tissue, Cervix, Duodenum, Fallopian tube, Liver, Parathyroid gland, Prostate, Salivary gland.
Medium only: skin cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MEF2D" OR ABSTRACT:"MEF2D" OR TITLE:"myocyte enhancer factor 2D" OR ABSTRACT:"myocyte enhancer factor 2D" OR TITLE:"Myocyte-specific enhancer factor 2D" OR ABSTRACT:"Myocyte-specific enhancer factor 2D") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MEF2D, not a curated reading list.